Global In situ Hybridization

In situ Hybridization Comprehensive Study by Application (Cancer Diagnosis, Immunology, Neuroscience, Cytology, Infectious Diseases), Technique (Fluorescence In Situ Hybridization (FISH) (DNA-FISH, RNA-FISH), Chromogenic In Situ Hybridization (CISH)), End User (Molecular Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions) Players and Region - Global Market Outlook to 2030

In situ Hybridization Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The major factors responsible for the growth of In situ hybridization market are rise in awareness about cancer along with technological developments in cancer therapeutics and increasing cancer prevalence. For instance, according to the American Cancer Society around 1.7 million new cancer cases are expected to be diagnosed in 2018 and over 609,640 Americans are expected to die of cancer in 2018. Hence, there has been rise in demand for increasing adoption of companion diagnostics and personalized medicine which is driving the demand for In situ hybridization. As it uses a labeled complementary RNA, DNA, or modified nucleic acid strand to localize a particular RNA or DNA sequence in a portion of tissue. Moreover, increasing government initiatives and increased healthcare expenditure in developing economies expected to fuel the market demand during the forecasted period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories, Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (United States), Thermo Fisher Scientific, Inc. (United States), Merck KGaA (Germany), PerkinElmer, Inc. (United States), Exiqon A/S (Denmark) and BioGenex Laboratories, Inc. (United States)


According to AMA, the market for In situ Hybridization is expected to register a CAGR of 20.3% during the forecast period to 2030. This growth is primarily driven by Rise in Cancer Prevalence, Growing Popularity of DNA Probe-Based Diagnostics and Increasing Government Spending In Healthcare Sector.

Globally, a noticeable market trend is evident Emphasizing On Technological Advancements in Cancer Therapeutics Major Players, such as Abbott Laboratories, Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (United States), Thermo Fisher Scientific, Inc. (United States), Merck KGaA (Germany), PerkinElmer, Inc. (United States), Exiqon A/S (Denmark) and BioGenex Laboratories, Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:

In July, 2021 Bio-Techne has expanded its Advanced Cell Diagnostics brand's RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed, paraffin-embedded (FFPE) and fixed and frozen samples for up to 12 targets.

Regulatory Insights:
“According to the Food and Drug Administration (FDA) for safety and effectiveness of an automated FISH enumeration system. A manufacturer who intends to market a device of this generic type should conform to the general controls of the Federal Food, Drug, and Cosmetic Act (the Act), including the premarket notification requirements described in 21 CFR 807 Subpart E and obtain a substantial equivalence determination from FDA before marketing the device.”

Influencing Trend:
Emphasizing On Technological Advancements in Cancer Therapeutics, Growing Clinical Research in Cancer by Pharmaceutical and Biotechnology Companies and Rising Focus on Automation of Diagnostic Tests

Market Growth Drivers:
Rise in Cancer Prevalence, Growing Popularity of DNA Probe-Based Diagnostics and Increasing Government Spending In Healthcare Sector

Challenges:
Availability of High-Throughput Whole Genome Sequencing and Other Advanced Technologies

Restraints:
Stringent Government Regulations Regarding In Situ Hybridization and Lack of Skilled Medical Professionals

Opportunities:
Rising Demand for Personalized Medicine and Companion Diagnostics, Increasing Applications in Genetic Diseases and Cancer Diagnostics and Growing Healthcare Infrastructure in the Developing Economies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in In situ Hybridization Market
- Analysis about New Entrants in In situ Hybridization Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, In situ Hybridization Study Sheds Light on
— The In situ Hybridization Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the In situ Hybridization industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where In situ Hybridization industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Cancer Diagnosis
  • Immunology
  • Neuroscience
  • Cytology
  • Infectious Diseases
By Technique
  • Fluorescence In Situ Hybridization (FISH) [DNA-FISH, RNA-FISH]
  • Chromogenic In Situ Hybridization (CISH)

By End User
  • Molecular Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutions

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Cancer Prevalence
      • 3.2.2. Growing Popularity of DNA Probe-Based Diagnostics
      • 3.2.3. Increasing Government Spending In Healthcare Sector
    • 3.3. Market Challenges
      • 3.3.1. Availability of High-Throughput Whole Genome Sequencing and Other Advanced Technologies
    • 3.4. Market Trends
      • 3.4.1. Emphasizing On Technological Advancements in Cancer Therapeutics
      • 3.4.2. Growing Clinical Research in Cancer by Pharmaceutical and Biotechnology Companies
      • 3.4.3. Rising Focus on Automation of Diagnostic Tests
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global In situ Hybridization, by Application, Technique, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global In situ Hybridization (Value)
      • 5.2.1. Global In situ Hybridization by: Application (Value)
        • 5.2.1.1. Cancer Diagnosis
        • 5.2.1.2. Immunology
        • 5.2.1.3. Neuroscience
        • 5.2.1.4. Cytology
        • 5.2.1.5. Infectious Diseases
      • 5.2.2. Global In situ Hybridization by: Technique (Value)
        • 5.2.2.1. Fluorescence In Situ Hybridization (FISH) [DNA-FISH, RNA-FISH]
        • 5.2.2.2. Chromogenic In Situ Hybridization (CISH)
      • 5.2.3. Global In situ Hybridization by: End User (Value)
        • 5.2.3.1. Molecular Diagnostic Laboratories
        • 5.2.3.2. Pharmaceutical & Biotechnology Companies
        • 5.2.3.3. Contract Research Organizations (CROs)
        • 5.2.3.4. Academic & Research Institutions
      • 5.2.4. Global In situ Hybridization Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. In situ Hybridization: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Leica Biosystems Nussloch GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Agilent Technologies (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck KGaA (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. PerkinElmer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Exiqon A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BioGenex Laboratories, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global In situ Hybridization Sale, by Application, Technique, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global In situ Hybridization (Value)
      • 7.2.1. Global In situ Hybridization by: Application (Value)
        • 7.2.1.1. Cancer Diagnosis
        • 7.2.1.2. Immunology
        • 7.2.1.3. Neuroscience
        • 7.2.1.4. Cytology
        • 7.2.1.5. Infectious Diseases
      • 7.2.2. Global In situ Hybridization by: Technique (Value)
        • 7.2.2.1. Fluorescence In Situ Hybridization (FISH) [DNA-FISH, RNA-FISH]
        • 7.2.2.2. Chromogenic In Situ Hybridization (CISH)
      • 7.2.3. Global In situ Hybridization by: End User (Value)
        • 7.2.3.1. Molecular Diagnostic Laboratories
        • 7.2.3.2. Pharmaceutical & Biotechnology Companies
        • 7.2.3.3. Contract Research Organizations (CROs)
        • 7.2.3.4. Academic & Research Institutions
      • 7.2.4. Global In situ Hybridization Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. In situ Hybridization: by Application(USD Million)
  • Table 2. In situ Hybridization Cancer Diagnosis , by Region USD Million (2018-2023)
  • Table 3. In situ Hybridization Immunology , by Region USD Million (2018-2023)
  • Table 4. In situ Hybridization Neuroscience , by Region USD Million (2018-2023)
  • Table 5. In situ Hybridization Cytology , by Region USD Million (2018-2023)
  • Table 6. In situ Hybridization Infectious Diseases , by Region USD Million (2018-2023)
  • Table 7. In situ Hybridization: by Technique(USD Million)
  • Table 8. In situ Hybridization Fluorescence In Situ Hybridization (FISH) [DNA-FISH, RNA-FISH] , by Region USD Million (2018-2023)
  • Table 9. In situ Hybridization Chromogenic In Situ Hybridization (CISH) , by Region USD Million (2018-2023)
  • Table 10. In situ Hybridization: by End User(USD Million)
  • Table 11. In situ Hybridization Molecular Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 12. In situ Hybridization Pharmaceutical & Biotechnology Companies , by Region USD Million (2018-2023)
  • Table 13. In situ Hybridization Contract Research Organizations (CROs) , by Region USD Million (2018-2023)
  • Table 14. In situ Hybridization Academic & Research Institutions , by Region USD Million (2018-2023)
  • Table 15. South America In situ Hybridization, by Country USD Million (2018-2023)
  • Table 16. South America In situ Hybridization, by Application USD Million (2018-2023)
  • Table 17. South America In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 18. South America In situ Hybridization, by End User USD Million (2018-2023)
  • Table 19. Brazil In situ Hybridization, by Application USD Million (2018-2023)
  • Table 20. Brazil In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 21. Brazil In situ Hybridization, by End User USD Million (2018-2023)
  • Table 22. Argentina In situ Hybridization, by Application USD Million (2018-2023)
  • Table 23. Argentina In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 24. Argentina In situ Hybridization, by End User USD Million (2018-2023)
  • Table 25. Rest of South America In situ Hybridization, by Application USD Million (2018-2023)
  • Table 26. Rest of South America In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 27. Rest of South America In situ Hybridization, by End User USD Million (2018-2023)
  • Table 28. Asia Pacific In situ Hybridization, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific In situ Hybridization, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 31. Asia Pacific In situ Hybridization, by End User USD Million (2018-2023)
  • Table 32. China In situ Hybridization, by Application USD Million (2018-2023)
  • Table 33. China In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 34. China In situ Hybridization, by End User USD Million (2018-2023)
  • Table 35. Japan In situ Hybridization, by Application USD Million (2018-2023)
  • Table 36. Japan In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 37. Japan In situ Hybridization, by End User USD Million (2018-2023)
  • Table 38. India In situ Hybridization, by Application USD Million (2018-2023)
  • Table 39. India In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 40. India In situ Hybridization, by End User USD Million (2018-2023)
  • Table 41. South Korea In situ Hybridization, by Application USD Million (2018-2023)
  • Table 42. South Korea In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 43. South Korea In situ Hybridization, by End User USD Million (2018-2023)
  • Table 44. Taiwan In situ Hybridization, by Application USD Million (2018-2023)
  • Table 45. Taiwan In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 46. Taiwan In situ Hybridization, by End User USD Million (2018-2023)
  • Table 47. Australia In situ Hybridization, by Application USD Million (2018-2023)
  • Table 48. Australia In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 49. Australia In situ Hybridization, by End User USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific In situ Hybridization, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific In situ Hybridization, by End User USD Million (2018-2023)
  • Table 53. Europe In situ Hybridization, by Country USD Million (2018-2023)
  • Table 54. Europe In situ Hybridization, by Application USD Million (2018-2023)
  • Table 55. Europe In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 56. Europe In situ Hybridization, by End User USD Million (2018-2023)
  • Table 57. Germany In situ Hybridization, by Application USD Million (2018-2023)
  • Table 58. Germany In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 59. Germany In situ Hybridization, by End User USD Million (2018-2023)
  • Table 60. France In situ Hybridization, by Application USD Million (2018-2023)
  • Table 61. France In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 62. France In situ Hybridization, by End User USD Million (2018-2023)
  • Table 63. Italy In situ Hybridization, by Application USD Million (2018-2023)
  • Table 64. Italy In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 65. Italy In situ Hybridization, by End User USD Million (2018-2023)
  • Table 66. United Kingdom In situ Hybridization, by Application USD Million (2018-2023)
  • Table 67. United Kingdom In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 68. United Kingdom In situ Hybridization, by End User USD Million (2018-2023)
  • Table 69. Netherlands In situ Hybridization, by Application USD Million (2018-2023)
  • Table 70. Netherlands In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 71. Netherlands In situ Hybridization, by End User USD Million (2018-2023)
  • Table 72. Rest of Europe In situ Hybridization, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 74. Rest of Europe In situ Hybridization, by End User USD Million (2018-2023)
  • Table 75. MEA In situ Hybridization, by Country USD Million (2018-2023)
  • Table 76. MEA In situ Hybridization, by Application USD Million (2018-2023)
  • Table 77. MEA In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 78. MEA In situ Hybridization, by End User USD Million (2018-2023)
  • Table 79. Middle East In situ Hybridization, by Application USD Million (2018-2023)
  • Table 80. Middle East In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 81. Middle East In situ Hybridization, by End User USD Million (2018-2023)
  • Table 82. Africa In situ Hybridization, by Application USD Million (2018-2023)
  • Table 83. Africa In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 84. Africa In situ Hybridization, by End User USD Million (2018-2023)
  • Table 85. North America In situ Hybridization, by Country USD Million (2018-2023)
  • Table 86. North America In situ Hybridization, by Application USD Million (2018-2023)
  • Table 87. North America In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 88. North America In situ Hybridization, by End User USD Million (2018-2023)
  • Table 89. United States In situ Hybridization, by Application USD Million (2018-2023)
  • Table 90. United States In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 91. United States In situ Hybridization, by End User USD Million (2018-2023)
  • Table 92. Canada In situ Hybridization, by Application USD Million (2018-2023)
  • Table 93. Canada In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 94. Canada In situ Hybridization, by End User USD Million (2018-2023)
  • Table 95. Mexico In situ Hybridization, by Application USD Million (2018-2023)
  • Table 96. Mexico In situ Hybridization, by Technique USD Million (2018-2023)
  • Table 97. Mexico In situ Hybridization, by End User USD Million (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. In situ Hybridization: by Application(USD Million)
  • Table 108. In situ Hybridization Cancer Diagnosis , by Region USD Million (2025-2030)
  • Table 109. In situ Hybridization Immunology , by Region USD Million (2025-2030)
  • Table 110. In situ Hybridization Neuroscience , by Region USD Million (2025-2030)
  • Table 111. In situ Hybridization Cytology , by Region USD Million (2025-2030)
  • Table 112. In situ Hybridization Infectious Diseases , by Region USD Million (2025-2030)
  • Table 113. In situ Hybridization: by Technique(USD Million)
  • Table 114. In situ Hybridization Fluorescence In Situ Hybridization (FISH) [DNA-FISH, RNA-FISH] , by Region USD Million (2025-2030)
  • Table 115. In situ Hybridization Chromogenic In Situ Hybridization (CISH) , by Region USD Million (2025-2030)
  • Table 116. In situ Hybridization: by End User(USD Million)
  • Table 117. In situ Hybridization Molecular Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 118. In situ Hybridization Pharmaceutical & Biotechnology Companies , by Region USD Million (2025-2030)
  • Table 119. In situ Hybridization Contract Research Organizations (CROs) , by Region USD Million (2025-2030)
  • Table 120. In situ Hybridization Academic & Research Institutions , by Region USD Million (2025-2030)
  • Table 121. South America In situ Hybridization, by Country USD Million (2025-2030)
  • Table 122. South America In situ Hybridization, by Application USD Million (2025-2030)
  • Table 123. South America In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 124. South America In situ Hybridization, by End User USD Million (2025-2030)
  • Table 125. Brazil In situ Hybridization, by Application USD Million (2025-2030)
  • Table 126. Brazil In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 127. Brazil In situ Hybridization, by End User USD Million (2025-2030)
  • Table 128. Argentina In situ Hybridization, by Application USD Million (2025-2030)
  • Table 129. Argentina In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 130. Argentina In situ Hybridization, by End User USD Million (2025-2030)
  • Table 131. Rest of South America In situ Hybridization, by Application USD Million (2025-2030)
  • Table 132. Rest of South America In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 133. Rest of South America In situ Hybridization, by End User USD Million (2025-2030)
  • Table 134. Asia Pacific In situ Hybridization, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific In situ Hybridization, by Application USD Million (2025-2030)
  • Table 136. Asia Pacific In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 137. Asia Pacific In situ Hybridization, by End User USD Million (2025-2030)
  • Table 138. China In situ Hybridization, by Application USD Million (2025-2030)
  • Table 139. China In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 140. China In situ Hybridization, by End User USD Million (2025-2030)
  • Table 141. Japan In situ Hybridization, by Application USD Million (2025-2030)
  • Table 142. Japan In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 143. Japan In situ Hybridization, by End User USD Million (2025-2030)
  • Table 144. India In situ Hybridization, by Application USD Million (2025-2030)
  • Table 145. India In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 146. India In situ Hybridization, by End User USD Million (2025-2030)
  • Table 147. South Korea In situ Hybridization, by Application USD Million (2025-2030)
  • Table 148. South Korea In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 149. South Korea In situ Hybridization, by End User USD Million (2025-2030)
  • Table 150. Taiwan In situ Hybridization, by Application USD Million (2025-2030)
  • Table 151. Taiwan In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 152. Taiwan In situ Hybridization, by End User USD Million (2025-2030)
  • Table 153. Australia In situ Hybridization, by Application USD Million (2025-2030)
  • Table 154. Australia In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 155. Australia In situ Hybridization, by End User USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific In situ Hybridization, by Application USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific In situ Hybridization, by End User USD Million (2025-2030)
  • Table 159. Europe In situ Hybridization, by Country USD Million (2025-2030)
  • Table 160. Europe In situ Hybridization, by Application USD Million (2025-2030)
  • Table 161. Europe In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 162. Europe In situ Hybridization, by End User USD Million (2025-2030)
  • Table 163. Germany In situ Hybridization, by Application USD Million (2025-2030)
  • Table 164. Germany In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 165. Germany In situ Hybridization, by End User USD Million (2025-2030)
  • Table 166. France In situ Hybridization, by Application USD Million (2025-2030)
  • Table 167. France In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 168. France In situ Hybridization, by End User USD Million (2025-2030)
  • Table 169. Italy In situ Hybridization, by Application USD Million (2025-2030)
  • Table 170. Italy In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 171. Italy In situ Hybridization, by End User USD Million (2025-2030)
  • Table 172. United Kingdom In situ Hybridization, by Application USD Million (2025-2030)
  • Table 173. United Kingdom In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 174. United Kingdom In situ Hybridization, by End User USD Million (2025-2030)
  • Table 175. Netherlands In situ Hybridization, by Application USD Million (2025-2030)
  • Table 176. Netherlands In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 177. Netherlands In situ Hybridization, by End User USD Million (2025-2030)
  • Table 178. Rest of Europe In situ Hybridization, by Application USD Million (2025-2030)
  • Table 179. Rest of Europe In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 180. Rest of Europe In situ Hybridization, by End User USD Million (2025-2030)
  • Table 181. MEA In situ Hybridization, by Country USD Million (2025-2030)
  • Table 182. MEA In situ Hybridization, by Application USD Million (2025-2030)
  • Table 183. MEA In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 184. MEA In situ Hybridization, by End User USD Million (2025-2030)
  • Table 185. Middle East In situ Hybridization, by Application USD Million (2025-2030)
  • Table 186. Middle East In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 187. Middle East In situ Hybridization, by End User USD Million (2025-2030)
  • Table 188. Africa In situ Hybridization, by Application USD Million (2025-2030)
  • Table 189. Africa In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 190. Africa In situ Hybridization, by End User USD Million (2025-2030)
  • Table 191. North America In situ Hybridization, by Country USD Million (2025-2030)
  • Table 192. North America In situ Hybridization, by Application USD Million (2025-2030)
  • Table 193. North America In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 194. North America In situ Hybridization, by End User USD Million (2025-2030)
  • Table 195. United States In situ Hybridization, by Application USD Million (2025-2030)
  • Table 196. United States In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 197. United States In situ Hybridization, by End User USD Million (2025-2030)
  • Table 198. Canada In situ Hybridization, by Application USD Million (2025-2030)
  • Table 199. Canada In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 200. Canada In situ Hybridization, by End User USD Million (2025-2030)
  • Table 201. Mexico In situ Hybridization, by Application USD Million (2025-2030)
  • Table 202. Mexico In situ Hybridization, by Technique USD Million (2025-2030)
  • Table 203. Mexico In situ Hybridization, by End User USD Million (2025-2030)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global In situ Hybridization: by Application USD Million (2018-2023)
  • Figure 5. Global In situ Hybridization: by Technique USD Million (2018-2023)
  • Figure 6. Global In situ Hybridization: by End User USD Million (2018-2023)
  • Figure 7. South America In situ Hybridization Share (%), by Country
  • Figure 8. Asia Pacific In situ Hybridization Share (%), by Country
  • Figure 9. Europe In situ Hybridization Share (%), by Country
  • Figure 10. MEA In situ Hybridization Share (%), by Country
  • Figure 11. North America In situ Hybridization Share (%), by Country
  • Figure 12. Global In situ Hybridization share by Players 2023 (%)
  • Figure 13. Global In situ Hybridization share by Players (Top 3) 2023(%)
  • Figure 14. Global In situ Hybridization share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 20. Leica Biosystems Nussloch GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Leica Biosystems Nussloch GmbH (Germany) Revenue: by Geography 2023
  • Figure 22. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 23. Agilent Technologies (United States) Revenue: by Geography 2023
  • Figure 24. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 28. PerkinElmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. PerkinElmer, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Exiqon A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 31. Exiqon A/S (Denmark) Revenue: by Geography 2023
  • Figure 32. BioGenex Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. BioGenex Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Global In situ Hybridization: by Application USD Million (2025-2030)
  • Figure 35. Global In situ Hybridization: by Technique USD Million (2025-2030)
  • Figure 36. Global In situ Hybridization: by End User USD Million (2025-2030)
  • Figure 37. South America In situ Hybridization Share (%), by Country
  • Figure 38. Asia Pacific In situ Hybridization Share (%), by Country
  • Figure 39. Europe In situ Hybridization Share (%), by Country
  • Figure 40. MEA In situ Hybridization Share (%), by Country
  • Figure 41. North America In situ Hybridization Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories, Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Leica Biosystems Nussloch GmbH (Germany)
  • Agilent Technologies (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • Merck KGaA (Germany)
  • PerkinElmer, Inc. (United States)
  • Exiqon A/S (Denmark)
  • BioGenex Laboratories, Inc. (United States)
Additional players considered in the study are as follows:
Advanced Cell Diagnostics, Inc. (United States) , Bio SB Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 237 Pages 65 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global In situ Hybridization Quantitative research analysis
Global In situ Hybridization Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global In situ Hybridization market are Abbott Laboratories, Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (United States), Thermo Fisher Scientific, Inc. (United States), Merck KGaA (Germany), PerkinElmer, Inc. (United States), Exiqon A/S (Denmark) and BioGenex Laboratories, Inc. (United States), to name a few.
is dominating the In situ Hybridization Market.
"Availability of High-Throughput Whole Genome Sequencing and Other Advanced Technologies" is seen as one of the major challenges by many Industry Players of In situ Hybridization Market
The In situ Hybridization market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The In situ Hybridization market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global In situ Hybridization Report?

Have a Query? Click Here

Other Related Reports

Healthcare Chatbots Comprehensive Study by Application (Symptom Check, Medical Assistance, Appointment Booking), End User (Patient, Healthcare Providers, Insurance Companies), Component (Software, S...
$ 3350
Atomic Spectroscopy Comprehensive Study by Application (Pharmaceuticals & Biotechnology, Geochemical/Mining, Industrial Chemistry, Environmental Testing, Food & Beverage Testing, Petrochemical, Other...
$ 3750
Tip-enhanced Raman Spectroscopy Comprehensive Study by Type (Confocal Microscope, Scanning Probe Microscope), Application (Material & Life Sciences, Art Conservation Science, Electrochemical Scanning...
$ 3500
Multichannel Pipettes Comprehensive Study by Type (Manual, Automatic), Application (Pharmaceutical, Biotech Companies, Hospitals, Research Institutions, Chemical Industry, Other), Number of Channels ...
$ 3350
Optical Microscope Comprehensive Study by Type (Simple Microscope, Compound Microscope, Digital Microscope, Others (Inverted Microscope, Stereo Microscope, and Comparison Microscope)), Application (R...
$ 3750
Antibody Engineering Services Comprehensive Study by Application (Research, Diagnostic, Therapeutics, Others), Services Type (Antibody cDNA Sequencing and Cloning, Humanization, Gene Synthesis, Trans...
$ 3650